Table 1.
Patient characteristics
| Clinical trial patients (n = 16) | |
|---|---|
| Sex, n (%) | |
| Male | 12 (75.0) |
| Age (years)a | 15.0 (4.6–16.8) |
| Ethnicity, n (%) | |
| Caucasian | 11 (68.8) |
| Asian | 0 (0) |
| African descent | 2 (12.5) |
| Other | 3 (18.9) |
| Bodyweight (kg)a | 50.3 (15.7–80.4) |
| Height (cm)a | 161 (101–179) |
| Genotype, n (%) | |
| CYP3A5 | |
| *1/*1 | 1 (6.3) |
| *1/*3 | 3 (18.9) |
| *3/*3 | 12 (75.0) |
| CYP3A4 | |
| *1/*1 | 13 (81.3) |
| *1/*1G | 2 (12.5) |
| *1G/*1G | 1 (6.3) |
| Primary diagnosis, n (%) | |
| CAKUT | 7 (43.8) |
| Glomerular kidney disease | 1 (6.3) |
| Cystic kidney disease/nephronophthisis | 3 (18.9) |
| Other/unknown | 5 (31.3) |
| RRT prior to kidney transplantation, n (%) | |
| Hemodialysis | 5 (31.3) |
| Peritoneal dialysis | 3 (18.9) |
| Pre-emptive | 8 (50.0) |
| Donor type, n (%) | |
| Living | 11 (68.8) |
| Deceased | 5 (31.3) |
| Number of HLA mismatches, n (%) | |
| 0 | 2 (12.5) |
| 1 | 1 (6.3) |
| 2 | 3 (18.9) |
| 3 | 7 (43.8) |
| 4 | 3 (18.9) |
CAKUT congenital anomalies of the kidney and the urinary tract, CYP cytochrome P450, HLA human leukocyte antigen, RRT renal replacement therapy
aPresented as median and range for continuous variables